Antibe Therapeutics ( ) - 株価, ニュースと分析TSX:ATE

ATE 株式概要

A biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. 詳細

ATE ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

リスク分析

収益が 100 万ドル未満 ( CA$0 )

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

意味のある時価総額がありません ( CA$16M )

Antibe Therapeutics Inc. 競合他社

SOL Global Investments

CNSX:SOL

CA$10.9m

Charlotte's Web Holdings

TSX:CWEB

CA$30.0m

MTL Cannabis

CNSX:MTLC

CA$20.5m

Quantum BioPharma

CNSX:QNTM

CA$13.3m

価格と性能

の歴代最高値、変動、値下がりまとめAntibe Therapeutics
過去の株価
現在の株価	CA$0.29
52週高値	CA$1.23
52週安値	CA$0.15
ベータ	0.19
11ヶ月の変化	0%
3ヶ月変化	-69.59%
1年変化	-42.16%
33年間の変化	-93.01%
5年間の変化	-90.92%
IPOからの変化	-94.64%

Recent updates

Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021

Jul 29

株主還元

	ATE	CA Pharmaceuticals	CA 市場
7D	0%	-6.1%	0.7%
1Y	-42.2%	-22.3%	21.7%

業界別リターン: ATE過去 1 年間で-22.3 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。

リターン対市場: ATEは、過去 1 年間で21.7 % のリターンを上げたCanadian市場を下回りました。

価格変動

Is ATE's price volatile compared to industry and market?
ATE volatility
ATE Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.5%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

安定した株価: ATEの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: 過去 1 年間のATEのボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2009	11	Dan Legault	www.antibethera.com

Antibe Therapeutics Inc. 基礎のまとめ

Antibe Therapeutics の収益と売上を時価総額と比較するとどうか。
ATE 基礎統計学
時価総額	CA$15.64m
収益（TTM）	-CA$18.24m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-0.9x

PER（株価収益率

ATE は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ATE 損益計算書（TTM）
収益	CA$0
売上原価	CA$0
売上総利益	CA$0
その他の費用	CA$18.24m
収益	-CA$18.24m

直近の収益報告

Dec 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.34
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	0%

ATE の長期的なパフォーマンスは？

過去の実績と比較を見る

ATE 株式概要

リスク分析

Antibe Therapeutics Inc. 競合他社

CNSX:SOL

CA$10.9m

TSX:CWEB

CA$30.0m

CNSX:MTLC

CA$20.5m

CNSX:QNTM

CA$13.3m

価格と性能

最新ニュース

Antibe Therapeutics Inc. Announces Board Resignations

Antibe Therapeutics Inc. Announces Board Resignations

New major risk - Market cap size

Nuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal Action

Price target decreased by 14% to CA$1.50

New minor risk - Profitability

Recent updates

Antibe Therapeutics Inc. Announces Board Resignations

Antibe Therapeutics Inc. Announces Board Resignations

New major risk - Market cap size

Nuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal Action

Price target decreased by 14% to CA$1.50

New minor risk - Profitability

Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?

Insufficient new directors

Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

New minor risk - Share price stability

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation

Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of Otenaproxesul

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Profitability

Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023

Forecast to breakeven in 2026

Price target increased by 12% to CA$2.35

We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully

Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of Directors

Price target increased to CA$2.35

Founder & Vice Chair recently sold CA$122k worth of stock

Price target decreased to CA$2.09

HANSAmed Limited completed the acquisition of Citagenix Inc from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million.

Antibe Therapeutics Inc. Provides Development Update for Otenaproxesul

Price target decreased to CA$2.09

First quarter 2023 earnings released: CA$0.11 loss per share (vs CA$0.13 loss in 1Q 2022)

Founder & Vice Chair recently sold CA$88k worth of stock

Price target decreased to CA$2.93

Antibe Therapeutics Inc., Annual General Meeting, Sep 09, 2022

Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs

HANSAmed Limited entered into an agreement to acquire Citagenix Inc. from Antibe Therapeutics Inc. (TSX:ATE) for CAD 6.5 million

Consensus revenue estimates increase by 112%

Price target decreased to CA$2.53

Consensus revenue estimates increase to CA$1.81m

Consensus forecasts updated

Second quarter 2022 earnings released: CA$0.16 loss per share (vs CA$0.21 loss in 2Q 2021)

President recently bought CA$100k worth of stock

Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business

First quarter 2022 earnings released: CA$0.13 loss per share (vs CA$0.16 loss in 1Q 2021)

Consensus forecasts updated

Price target decreased to CA$10.20

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings released: CA$0.66 loss per share (vs CA$0.71 loss in FY 2020)

Price target decreased to CA$15.09

Independent Chair of the Board recently sold CA$400k worth of stock

Antibe Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 35.1 million.

Price target raised to CA$16.96

Third quarter 2021 earnings released: CA$0.15 loss per share (vs CA$0.15 loss in 3Q 2020)

Revenue and earnings beat expectations

Analysts update estimates

Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook

Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China

New 90-day high: CA$5.76

Antibe Therapeutics Inc. Appoints Don Haut to Its Partnering Advisory Team

We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate

Analysts update estimates

Analysts update estimates